William Marvin Mitchell, M.D., Ph.D. was appointed the Chairman of the Board of Hemispherx Biopharma, the maker of Ampligen in February 2016 after serving as a Director since July 1998. Dr. Mitchell is a Professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine, Nashville, Tennessee, and is a board certified physician. He replaced Dr. William Carter, the founder of the company and the inventor of Ampligen.
Notable studies[edit | edit source]
- 1995, Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen(Abstract)
- 2007, Cross-Protection against H5N1 Influenza Virus Infection Is Afforded by Intranasal Inoculation with Seasonal Trivalent Inactivated Influenza Vaccine
- 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome
- 2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod
- 2016, William M. Mitchell published a review in the journal, Expert Review of Clinical Pharmacology that stated: "Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe."
- 2017, Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
References[edit | edit source]
- Hemispherx Biopharma Board of Directors
- Loyd, Linda Lo (February 24, 2016), "Hemispherx fires founder, chairman William A. Carter", Philly.com
- Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995), "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen", Journal of Chronic Fatigue Syndrome, 1 (1): 35-53, doi:10.1300/J092v01n01_04
- Takeshi Ichinohe, Shin-ichi Tamura, Akira Kawaguchi, Ai Ninomiya, Masaki Imai, Shigeyuki Itamura, Takato Odagiri, Masato Tashiro, Hidehiro Takahashi, Hirofumi Sawa, William M. Mitchell, David R. Strayer, William A. Carter, Joe Chiba, Takeshi Kurata, Tetsutaro Sata and Hideki Hasegawa. The Journal of Infectious Diseases, Vol. 196, No. 9 (Nov. 1, 2007), pp. 1313-1320. Url: http://www.jstor.org/stable/30086851
- Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
- Strayer, David R; Stouch, Bruce C; Stevens, Staci R.; Bateman, Lucinda; Lapp, Charles W; Peterson, Daniel L; Carter, William A; Mitchell, William M (August 8, 2015), "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod" (PDF), Journal of Drug Research and Development, 1 (1), doi:10.16966/2470-1009.103
- Mitchell, WM (June 2016), "Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).", Expert Review of Clinical Pharmacology, 9 (6): 755-70, doi:10.1586/17512433.2016.1172960, PMID 27045557
- Glen J. Weiss, Julia Beck, Donald P. Braun, Kristen Bornemann-Kolatzki, Heather Barilla, Rhiannon Cubello, Walter Quan Jr, Ashish Sangal, Vivek Khemka, Jordan Waypa, William M. Mitchell, Howard Urnovitz and Ekkehard Schütz; Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy; Clin Cancer Res; 23(17); 5074-81. doi:10.1158/1078-0432.CCR-17-0231
double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)
agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.
phase three Last phase of clinical trials before a drug can be approved for public use. Whereas Phase one assesses basic safety, and Phase two assesses basic efficacy, Phase three uses many trial participants to fully assess both safety and efficacy, and overall benefit/risk.